JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Debanjana Chatterjee’s rating is based on several factors, including the recent updates from Intellia’s Phase 3 programs, which suggest that the market’s reaction to safety concerns may be exaggerated. The management’s commentary and insights from key opinion leaders indicate that the Grade 4 liver transaminase elevation observed in the MAGNITUDE study is not expected to impact patient recruitment or the overall progress of the trial.
Despite the liver enzyme elevation, it is considered asymptomatic and is expected to resolve without medical intervention. The management anticipates that the transaminase levels will normalize within the next 6-8 weeks. Additionally, the enrollment in the MAGNITUDE trial is proceeding smoothly, with no significant obstacles. The feedback from medical experts suggests that the adverse events are reversible and transient, and the single event is unlikely to deter future patient referrals or prescriptions.